Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a Healthcare company (Biotechnology) with a market capitalization of $113M. The Maz Rating grades it against the other companies in its sector.
Inovio Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.63, Inovio Pharmaceuticals, Inc. trades at 374.5x sales. Over the last twelve months it generated about $300746 of revenue and a net loss of $55M. It runs a gross margin of -401.7%, an operating margin of -25953.8% and a net margin of -23798.9%. It shows return on equity of -46473.1%, return on invested capital of 291.2% and a free cash flow yield of -66.3%. On the balance sheet: a debt-to-equity ratio of -0.21 and a current ratio of 0.57. Over the past 52 weeks the share price ranged from $0.56 to $2.72, with a beta of 1.61.
Inovio Pharmaceuticals, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 11 Buy, 4 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.